Christine I Hudson

US Patent:

7470787, Dec 30, 2008

Filed:

Jul 11, 2006

Appl. No.:

11/485172

Inventors:

Mitchell A. deLong - Raleigh NC, US
Marcos L. Sznaidman - Durham NC, US
Robert H. Oakley - Durham NC, US
Allen E. Eckhardt - Durham NC, US
Christine Hudson - Durham NC, US
Jeffrey D. Yingling - Apex NC, US
Michael Peel - Chapel Hill NC, US
Thomas E. Richardson - Durham NC, US
Claire Louise Murray - Chapel Hill NC, US
Brian H. Heasley - Wake Forest NC, US
Paresma R. Patel - San Diego CA, US

Assignee:

Aerie Pharmaceuticals, Inc. - Research Triangle Park NC

International Classification:

C07D 217/00
C07D 401/00
C07D 215/00

US Classification:

546146, 546148, 546152

Abstract:

Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

US Patent:

20070135499, Jun 14, 2007

Filed:

Jul 11, 2006

Appl. No.:

11/485182

Inventors:

Mitchell deLong - Raleigh NC, US
Marcos Sznaidman - Durham NC, US
Robert Oakley - Durham NC, US
Allen Eckhardt - Durham NC, US
Christine Hudson - Durham NC, US
Jeffrey Yingling - Apex NC, US
Michael Peel - Chapel Hill NC, US
Thomas Richardson - Durham NC, US
Clare Murray - Chapel Hill NC, US
Brian Heasley - Wake Forest NC, US
Paresma Patel - San Diego CA, US

Assignee:

Aerie Pharmaceuticals, Inc. - Research Triangle Park NC

International Classification:

A61K 31/44

US Classification:

514357000, 546332000

Abstract:

Hydrazide compounds with GPCR desensitization inhibitory activity are provided that may be used to influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the hydrazide compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions controlled or influenced by GPCRs are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

US Patent:

20090069371, Mar 12, 2009

Filed:

Nov 20, 2008

Appl. No.:

12/274887

Inventors:

Mitchell A. deLong - Raleigh NC, US
Marcos L. Sznaidman - Durham NC, US
Robert H. Oakley - Durham NC, US
Allen E. Eckhardt - Durham NC, US
Christine Hudson - Durham NC, US
Jeffrey D. Yingling - Apex NC, US
Michael Peel - Chapel Hill NC, US
Thomas E. Richardson - Durham NC, US
Clare Louise Murray - Chapel Hill NC, US
Brian H. Heasley - Wake Forest NC, US
Paresma R. Patel - San Diego CA, US

Assignee:

Aerie Pharmaceuticals, Inc. - Research Triangle Park NC

International Classification:

A61K 31/47
C07D 217/22
A61P 27/02
A61P 9/00
A61P 1/00
A61P 15/08
A61P 35/00
A61P 19/08
C12N 5/00

US Classification:

514310, 546143, 435325

Abstract:

Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

US Patent:

20100093790, Apr 15, 2010

Filed:

Dec 16, 2009

Appl. No.:

12/639670

Inventors:

Mitchell A. deLong - Raleigh NC, US
Marcos L. Sznaidman - Durham NC, US
Robert H. Oakley - Durham NC, US
Allen E. Eckhardt - Durham NC, US
Christine Hudson - Durham NC, US
Jeffrey D. Yingling - Apex NC, US
Michael Peel - Chapel Hill NC, US
Thomas E. Richardson - Durham NC, US
Clare Louise Murray - Chapel Hill NC, US
Brian H. Heasley - Wake Forest NC, US
Paresma R. Patel - San Diego CA, US

Assignee:

AERIE PHARMACEUTICALS, INC. - Research Triangle Park NC

International Classification:

A61K 31/472
C07D 217/02
C07D 401/12
C12N 5/00
A61K 31/4725
A61P 27/02
A61P 19/00
A61P 9/00
A61P 13/12

US Classification:

514310, 546143, 435375

Abstract:

Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.